| 证券代码：688277 证券简称：天智航 公告编号：2025-024 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 北京天智航医疗科技股份有限公司 | | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | 重要内容提示： | | | | | | | | 本次会议是否有被否决议案：无 | ? | | | | | | | 会议召开和出席情况 | 一、 | | | | | | | 股东大会召开的时间：2025 年 月 20 日 | （一） | 5 | | | | | | 股东大会召开的地点：北京市海淀区建枫路（南延）中关村西三旗金隅 | （二） | | | | | | | 8 号楼北京天智航医疗科技股份有限公司会议室 | 科技园 号院 2 | | | | | | | 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | （三） | | | | | | | ...

证券代码：688277 证券简称：天智航 公告编号：2025-024 北京天智航医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长张送根先生因工作原因未能现场出 席会议，经半数以上董事共同推举公司董事徐进先生主持本次会议，本次会议采 用现场投票与网络投票相结合的方式召开。本次会议的召集、召开及表决方式符 合《公司法》《上海证券交易所科创板股票上市规则》及《公司章程》的相关规 定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席8人，董事长张送根先生因工作原因请假未出席本次 会议； 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 20 日 （二） 股东大会召开的地点：北京市海淀区建枫路（南延）中关村西三旗金隅 科技园 8 号院 2 号楼北京天智航医疗科技股份有限公司会 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于北京天智航医疗科技股份有限公司 2024 年年度股东大会的法律意见书 康达股会字【2025】第 0258 号 致：天智航医疗科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受北京天智航医疗科技 股份有限公司（以下简称"公司"）的委托，就公司 2024 年年度股东大会 （以下简称"本次会议"）的相关事宜出具《北京市康达律师事务所关于北 京天智航医疗科技股份有限公司 2024 年年度股东大会的法律意见书》（以 ...

天智航公告，股东先进制造基金拟减持不超过679万股，计划减持比例不超过1.5%。股东京津冀基金拟 减持不超过679万股，计划减持比例不超过1.5%。减持方式包括集中竞价和大宗交易，减持期间为2025 年6月12日至2025年9月11日。减持原因是自身资金需求。 ...

Core Points - The annual general meeting of Beijing Tianzhihang Medical Technology Co., Ltd. is scheduled for May 20, 2025, at 10:00 AM, combining on-site and online voting methods [4][5][12] - The company reported a net profit of -121.13 million yuan for 2024, with no distributable profits available [10][11] - The company plans to issue shares to specific targets, with a total financing amount not exceeding 1 billion yuan [12][13] Meeting Procedures - Attendees must confirm their identity upon arrival, and the meeting will follow a predetermined agenda for discussion and voting [2][3] - Shareholders have the right to speak, inquire, and vote, but must adhere to time limits and order during discussions [2][3] - The meeting will be witnessed by a legal representative from a law firm, ensuring compliance with legal standards [3][4] Financial Performance - The company achieved a total revenue of 178.84 million yuan in 2024, with significant contributions from orthopedic surgical robots and related services [15][16] - The sales of consumables increased by 55.27% from 33.88 million yuan in 2023 to 52.60 million yuan in 2024 [15][16] - The company has conducted over 39,000 surgeries using its orthopedic surgical robots in 2024, with a cumulative total exceeding 100,000 surgeries by the end of the year [16][17] Product Development - The company expanded its product offerings, gaining approval for new applications of its orthopedic surgical robots, including total hip replacement surgeries [16][17] - The orthopedic surgical navigation system received CE certification, marking a significant step in the company's international expansion strategy [17] Governance and Oversight - The board of directors held 12 meetings in 2024, addressing major operational decisions and ensuring compliance with legal and regulatory requirements [19][20] - The supervisory board conducted 12 meetings, overseeing the company's operations and ensuring adherence to financial regulations [23][24] - The company emphasizes investor relations, maintaining open communication channels to enhance transparency and protect shareholder interests [21][22]

北京天智航医疗科技股份有限公司 2024 年年度股东大会会议资料 北京天智航医疗科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 | | | 北京天智航医疗科技股份有限公司 2024 年年度股东大会会议资料 北京天智航医疗科技股份有限公司 2024 年年度股东大会会议须知 各位股东及股东代表： 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》、 中国证监会《上市公司股东大会规则》以及《北京天智航医疗科技股份有限公司 章程》《北京天智航医疗科技股份有限公司股东大会议事规则》的相关规定，特 制定 2024 年年度股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请出 席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格，在会议 主持人宣布现场出席会议的股东和代理人人数及所持有的表决权数量之前，会议 登记应当终止。 三、会议按照会议通知 ...

Core Viewpoint - Tianzhihang is a leading enterprise in the orthopedic surgical robot industry in China, focusing on the research, production, sales, and service of orthopedic surgical navigation robots [1] Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in orthopedic surgical navigation robots and related equipment, consumables, technical services, and surgical center engineering [1] - The company is recognized as one of the top 10 robotics companies in China and serves as a key research center for national and local medical robotics [1] Financial Performance - For Q1 2025, the company reported revenue of 58.58 million yuan, a year-on-year increase of 102.40% [1] - The net profit for the same period was -13.20 million yuan, reflecting a year-on-year decrease of 31.22% [1] - The gross profit margin stood at 75.12% [1] Shareholder Information - As of March 31, 2025, the number of shareholders reached 16,633, an increase of 1,520 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - The latest closing price for Tianzhihang was 12.48 yuan, down 2.73%, with a price-to-book ratio of 4.32 and a total market capitalization of 5.649 billion yuan [1][2]

Group 1 - The core viewpoint of the articles highlights Tianzhihang's position as a leading company in the orthopedic surgical robot industry in China, with a focus on research, production, sales, and service of surgical navigation robots [1][2] - As of the first quarter of 2025, Tianzhihang reported a revenue of 58.58 million yuan, representing a year-on-year increase of 102.40%, while the net profit was -13.20 million yuan, a decrease of 31.22% year-on-year, with a gross margin of 75.12% [1] - The company's stock closed at 12.96 yuan, up 2.86%, with a latest price-to-book ratio of 4.49 and a total market capitalization of 5.867 billion yuan [1] Group 2 - Tianzhihang is among six institutions holding shares, with a total of 90.76 million shares valued at 1.126 billion yuan [1] - The average price-to-earnings (P/E) ratio for the industry is 48.90, while Tianzhihang's P/E (TTM) is -47.21, indicating a significant deviation from industry norms [2] - The company is recognized as a top 10 member of the robotics sector in China and serves as a research center for medical robots [1]

Core Viewpoint - The company Tianzhihang-U (688277.SH) is facing challenges in the surgical robot market, with a significant decline in revenue and ongoing losses, despite a slight improvement in loss reduction and a rebound in business volume in early 2024 [1][3]. Financial Performance - In 2023, the company reported a revenue of 1.79 billion yuan, a year-on-year decrease of 14.85%, and a net profit loss of 1.21 billion yuan, which is a 22.54% reduction in losses compared to the previous year [1]. - The first quarter of 2024 showed a significant recovery, with revenue reaching 585.84 million yuan, more than doubling year-on-year [4][6]. Revenue Breakdown - The company's revenue from surgical navigation robots, consumables, and technical services accounted for 1.72 billion yuan, with the surgical navigation robots generating 742.96 million yuan, a 47.39% decline year-on-year [3]. - Consumables and technical services saw a notable increase, with consumables sales reaching 548.55 million yuan (up 55.27%) and technical services generating 429.58 million yuan (up 103.71%) [3][4]. Market Dynamics - The surgical robot market is becoming increasingly competitive, with 64 companies and 115 products approved by the end of 2024, particularly in the orthopedic segment, which accounts for 47% of the total approved products [5]. - The company maintains the largest market share domestically, although it has seen a decline [6]. International Strategy and Risks - The company faces risks from increased competition and potential tariff fluctuations affecting the supply of critical components from international manufacturers [6][7]. - The international revenue dropped from 6.39 million yuan in 2023 to zero, indicating challenges in executing its internationalization strategy [7].